| Functionalization of cobalt porphyrin–phospholipid bilayers with his-tagged ligands and antigens S Shao, J Geng, H Ah Yi, S Gogia, S Neelamegham, A Jacobs, JF Lovell Nature chemistry 7 (5), 438-446, 2015 | 136 | 2015 |
| Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion AS Dimitrov, A Jacobs, CM Finnegan, G Stiegler, H Katinger, ... Biochemistry 46 (5), 1398-1401, 2007 | 117 | 2007 |
| Heparin binding by the HIV‐1 tat protein transduction domain S Hakansson, A Jacobs, M Caffrey Protein Science 10 (10), 2138-2139, 2001 | 77 | 2001 |
| Affitoxin—a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors R Zielinski, I Lyakhov, A Jacobs, O Chertov, G Kramer-Marek, N Francella, ... Journal of Immunotherapy 32 (8), 817-825, 2009 | 75 | 2009 |
| De novo synthesis and cellular uptake of organic nanocapsules with tunable surface chemistry K Huang, A Jacobs, J Rzayev Biomacromolecules 12 (6), 2327-2334, 2011 | 62 | 2011 |
| Alanine scanning mutants of the HIV gp41 loop A Jacobs, J Sen, L Rong, M Caffrey Journal of Biological Chemistry 280 (29), 27284-27288, 2005 | 60 | 2005 |
| Development of non-natural flavanones as antimicrobial agents ZL Fowler, K Shah, JC Panepinto, A Jacobs, MAG Koffas PLoS One 6 (10), e25681, 2011 | 59 | 2011 |
| The Conjugal Intermediate of Plasmid RSF1010 Inhibits Agrobacterium tumefaciens Virulence and VirB-Dependent Export of VirE2 LE Stahl, A Jacobs, AN Binns Journal of bacteriology 180 (15), 3933-3939, 1998 | 58 | 1998 |
| Inhibition of HIV entry by targeting the envelope transmembrane subunit gp41 H A Yi, B C Fochtman, R C Rizzo, A Jacobs Current HIV research 14 (3), 283-294, 2016 | 54 | 2016 |
| Role of the HIV gp120 conserved domain 5 in processing and viral entry J Sen, A Jacobs, M Caffrey Biochemistry 47 (30), 7788-7795, 2008 | 41 | 2008 |
| Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy H Garg, M Viard, A Jacobs, R Blumenthal Current topics in medicinal chemistry 11 (24), 2947-2958, 2011 | 38 | 2011 |
| Solution structure of the HIV gp120 C5 domain L Guilhaudis, A Jacobs, M Caffrey European journal of biochemistry 269 (19), 4860-4867, 2002 | 35 | 2002 |
| HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development A Jacobs, H Garg, M Viard, Y Raviv, A Puri, R Blumenthal Vaccine 26 (24), 3026-3035, 2008 | 30 | 2008 |
| Solution Structure of the Coxsackievirus and Adenovirus Receptor Domain 1, S Jiang, A Jacobs, TM Laue, M Caffrey Biochemistry 43 (7), 1847-1853, 2004 | 29 | 2004 |
| The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160 J Sen, A Jacobs, H Jiang, L Rong, M Caffrey Protein science 16 (6), 1236-1241, 2007 | 27 | 2007 |
| Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation WJ Allen, HA Yi, M Gochin, A Jacobs, RC Rizzo Bioorganic & medicinal chemistry letters 25 (14), 2853-2859, 2015 | 25 | 2015 |
| A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex A Jacobs, O Quraishi, X Huang, N Bousquet-Gagnon, G Nault, ... Journal of biological chemistry 282 (44), 32406-32413, 2007 | 25 | 2007 |
| Mapping the Vif–A3G interaction using peptide arrays: a basis for anti-HIV lead peptides TH Reingewertz, E Britan-Rosich, S Rotem-Bamberger, M Viard, ... Bioorganic & medicinal chemistry 21 (12), 3523-3532, 2013 | 16 | 2013 |
| Permanent inhibition of viral entry by covalent entrapment of HIV gp41 on the virus surface HA Yi, B Diaz-Aguilar, D Bridon, O Quraishi, A Jacobs Biochemistry 50 (32), 6966-6972, 2011 | 15 | 2011 |
| Thermostability of the HIV gp41 wild-type and loop mutations A Jacobs, C Simon, M Caffrey Protein and peptide letters 13 (5), 477-480, 2006 | 15 | 2006 |
